While previous data demonstrated no predictive/prognostic role of the expression of CD8 or PD-L1 in patients with metastatic MSS/pMMR colorectal cancer treated with regorafenib plus avelumab [18], another study suggested CD8 and PD-L1 might be potential biomarkers in MSS/pMMR colorectal cancer treated with regorafenib plus nivolumab [15]. Here, CD8A is linked to colorectal cancer.